Context Therapeutics (CNTX) Prepaid Assets (2020 - 2026)
Context Therapeutics (CNTX) posted Prepaid Assets of $4.0 million for Q1 2026, up 69.1% sequentially from $2.4 million in Q4 2025, and up 18.04% YoY from $3.4 million in Q1 2025.
Context Therapeutics (CNTX) Prepaid Assets (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Prepaid Assets for 7 years, with the latest figure at $4.0 million in Q1 2026.
- Quarterly Prepaid Assets rose 18.04% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 18.04% YoY) and the FY2025 annual result came in at $2.4 million, down 31.96% from the prior year.
- Prepaid Assets advanced to $4.0 million in Q1 2026 per CNTX's latest filing, from $2.4 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.0 million in Q1 2026 and troughed at $949489.0 in Q1 2024.
- A 5-year average of $2.2 million and a median of $2.1 million in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets soared 13568.19% in 2022, then slumped 55.14% in 2024.
- Over 5 years, Prepaid Assets stood at $2.4 million in 2022, then tumbled by 32.21% to $1.6 million in 2023, then surged by 116.99% to $3.5 million in 2024, then tumbled by 31.96% to $2.4 million in 2025, then jumped by 69.1% to $4.0 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.0 million, $2.4 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.83 Mn |
| Mar 31, 2026 | 3.99 Mn |
| Dec 31, 2025 | 2.36 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.38 Mn |
| Dec 31, 2024 | 3.47 Mn |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 949,489.00 |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 2.12 Mn |
| Dec 31, 2022 | 2.36 Mn |
| Sep 30, 2022 | 2.51 Mn |
| Jun 30, 2022 | 1.58 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 1.62 Mn |
| Sep 30, 2021 | 18,379.00 |